PURPOSE: To study the effectiveness of a peptide targeted nanoglobular Gd-DOTA complexes for MR molecular imaging of prostate cancer in a mouse orthotopic PC-3 prostate cancer model. METHODS: A CLT1 (CGLIIQKNEC) peptide-targeted generation 2 nanoglobular Gd-DOTA monoamide conjugate [CLT1-G2-(Gd-DOTA)] was used for imaging fibrin-fibronectin complexes in prostate tumor using a non-specific peptide KAREC modified conjugate, KAREC-G2-(Gd-DOTA) as a control. Cy5 conjugates of CLT1 and KAREC were synthesized for binding studies. Orthotopic PC-3 prostate tumors were established in the prostate of athymic male nude mice. MRI study was performed on a Bruker 7T small animal MRI system. RESULTS: CLT1 peptide showed specific binding in the prostate tumor with no binding in normal tissues. The control peptide had little binding in normal and tumor tissues. CLT1-G2-(Gd-DOTA) resulted in stronger contrast enhancement in tumor tissue than KAREC-G2-(Gd-DOTA). CLT1-G2-(Gd-DOTA) generated ~100% increase in contrast-to-noise ratio (CNR) in the tumor compared to precontrast CNR at 1 min post-injection, while KAREC-G2-(Gd-DOTA) resulted in 8% increase. CONCLUSION: CLT1-G2-(Gd-DOTA) is a promising molecular MRI contrast agent for fibrin-fibronectin complexes in tumor stroma. It has potential for diagnosis and assessing prognosis of malignant tumors with MRI.
PURPOSE: To study the effectiveness of a peptide targeted nanoglobular Gd-DOTA complexes for MR molecular imaging of prostate cancer in a mouse orthotopic PC-3prostate cancer model. METHODS: A CLT1 (CGLIIQKNEC) peptide-targeted generation 2 nanoglobular Gd-DOTA monoamide conjugate [CLT1-G2-(Gd-DOTA)] was used for imaging fibrin-fibronectin complexes in prostate tumor using a non-specific peptide KAREC modified conjugate, KAREC-G2-(Gd-DOTA) as a control. Cy5 conjugates of CLT1 and KAREC were synthesized for binding studies. Orthotopic PC-3prostate tumors were established in the prostate of athymic male nude mice. MRI study was performed on a Bruker 7T small animal MRI system. RESULTS: CLT1 peptide showed specific binding in the prostate tumor with no binding in normal tissues. The control peptide had little binding in normal and tumor tissues. CLT1-G2-(Gd-DOTA) resulted in stronger contrast enhancement in tumor tissue than KAREC-G2-(Gd-DOTA). CLT1-G2-(Gd-DOTA) generated ~100% increase in contrast-to-noise ratio (CNR) in the tumor compared to precontrast CNR at 1 min post-injection, while KAREC-G2-(Gd-DOTA) resulted in 8% increase. CONCLUSION: CLT1-G2-(Gd-DOTA) is a promising molecular MRI contrast agent for fibrin-fibronectin complexes in tumor stroma. It has potential for diagnosis and assessing prognosis of malignant tumors with MRI.
Authors: David M Schuster; Bital Savir-Baruch; Peter T Nieh; Viraj A Master; Raghuveer K Halkar; Peter J Rossi; Melinda M Lewis; Jonathon A Nye; Weiping Yu; F DuBois Bowman; Mark M Goodman Journal: Radiology Date: 2011-04-14 Impact factor: 11.105
Authors: Dipanjan Pan; Shelton D Caruthers; Junjie Chen; Patrick M Winter; Angana SenPan; Anne H Schmieder; Samuel A Wickline; Gregory M Lanza Journal: Future Med Chem Date: 2010-03 Impact factor: 3.808
Authors: William J Rieter; Thomas E Keane; Mark A Ahlman; Clayton T Ellis; Kenneth M Spicer; Leonie L Gordon Journal: Clin Nucl Med Date: 2011-10 Impact factor: 7.794
Authors: Monica Santimaria; Giovanni Moscatelli; Giuseppe L Viale; Leonardo Giovannoni; Giovanni Neri; Francesca Viti; Alessandra Leprini; Laura Borsi; Patrizia Castellani; Luciano Zardi; Dario Neri; Pietro Riva Journal: Clin Cancer Res Date: 2003-02 Impact factor: 12.531
Authors: L Chaabane; L Tei; L Miragoli; L Lattuada; M von Wronski; F Uggeri; V Lorusso; S Aime Journal: Mol Imaging Biol Date: 2015-12 Impact factor: 3.488
Authors: Xueming Wu; Susan M Burden-Gulley; Guan-Ping Yu; Mingqian Tan; Daniel Lindner; Susann M Brady-Kalnay; Zheng-Rong Lu Journal: Bioconjug Chem Date: 2012-08-01 Impact factor: 4.774
Authors: Evan R Trivedi; Zhidong Ma; Emily A Waters; Keith W Macrenaris; Rohit Subramanian; Anthony G M Barrett; Thomas J Meade; Brian M Hoffman Journal: Contrast Media Mol Imaging Date: 2014 Jul-Aug Impact factor: 3.161
Authors: April M Chow; Mingqian Tan; Darwin S Gao; Shu Juan Fan; Jerry S Cheung; Kwan Man; Zheng-Rong Lu; Ed X Wu Journal: Invest Radiol Date: 2013-01 Impact factor: 6.016